Following the recent announcement of the innovative mentoring initiative, called TechBuddy, run by Eastern AHSN and Cambridge Network to match up technology innovators in the region with people leading work in the NHS, the scheme is looking for applications from new, interested parties.
Bringing together strengths in healthcare and technology holds enormous promise for the nation’s health and wealth. There is still, however, huge scope for better understanding between technology companies and those leading work in the NHS.
The TechBuddy scheme is designed to help bridge this gap between the…
27 June 2019, Cambridge, UK: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.
Dr Haurum has over 20 years’ experience in the international biotech industry. Previously John was Chief Executive Officer of F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies, with multiple strategic collaborations with AbbVie, Merck KGaA, Denali and Boehringer…
CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the…
BioBridge Ltd, the UK-based bioscience innovation consultancy, announces the start of a new working relationship with Osprey Consultants LLC, a US-based animal health consultancy specialising in veterinary medicine product development and commercialisation. BioBridge and Osprey will assist each other in providing services for their respective clients.
Osprey’s founder, Dr. William Symington, has, similar to BioBridge’s Meredith Lloyd-Evans, long-term experience in the animal health industry. His 40 years of experience has covered all domesticated species and all key global regions.…
Coventry, UK, 25th June 2019 / Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®, has appointed John Burt as Chief Executive Officer, effective 24 June 2019. Nigel Davis, the current CEO, will remain with the Company as Chief Business Officer.
Medherant has completed two Phase I clinical studies with an Ibuprofen TEPI Patch and is discussing its further development with potential commercial partners whilst it focuses on the development of patch products to treat…
Collaboration will initially accelerate C4X Discovery’s Parkinson’s disease drug discovery pipeline
Cambridge, UK, 25 June, 2019: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announced they have signed a neurodegeneration drug discovery collaboration agreement. Combining the two companies’ technology platforms to validate novel targets, the initial focus will be on Parkinson’s disease.
Under the terms of the agreement, PhoreMost’s next-…
With two acquisitions complete this year, Entrust Resource Solutions are now creating new jobs across the UK by adding a specialist Resourcing Team to their business.
Entrust Resource Solutions recently announced an ambitious growth and acquisition strategy. This started with the addition of two resourcing consultancies to their portfolio, with Horton International (UK) and SCI Search and Selection joining Entrust People. To keep up with their rate of growth and better support their team, the business is now creating a new Resourcing Team.
The Resourcing Team will primarily support the…
ScreenIn3D, a partner of AMSBIO, has received a share of the £1 million plus prize pot and will receive ongoing support from partners of Scottish Edge - a respected regional business support agency.Scottish EDGE (https://www.scottishedge.com/) runs a competition aimed at identifying and supporting Scotland’s up-and-coming, innovative, high-growth potential entrepreneurial talent. The winning businesses for the latest Round 14 awards came from 37 multisector finalists, shortlisted from more than 280 applicants, who pitched their business idea live at Glasgow’s Technology and Innovation Centre…
Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines
Catalent will continue to manufacture products for Bristol-Myers Squibb while offering other customers access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms
(NEW YORK and SOMERSET, N.J., June 19, 2019) – Bristol-Myers Squibb Company (NYSE:BMY) and Catalent, Inc. (NYSE: CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing…
Reading Scientific Services Ltd (RSSL) is tripling the size of its pharmaceutical microbiology laboratory with the opening of a new, state-of-the-art facility in Wokingham. The move follows sustained market demand for the consultancy’s microbiological analysis services. It not only provides the operational space to significantly increase capacity, but also signals a commitment to the future expansion of test methods and staff levels.
“We have experienced tremendous growth over recent years and have simply outgrown the existing laboratory at our head office in Reading. This purpose-designed…